David Planchard

Institut Gustave Roussy ORCID: 0000-0002-1565-8310

1

h-index

1

Publications

1,406

Citations

Publications

1 shown

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more

2015 The Lancet Oncology 1406 citations

Frequent Co-Authors

Naiyer A. Rizvi

Columbia University Irving Medical Center

Julien Mazières

Université Toulouse III - Paul Sabatier

Thomas E. Stinchcombe

University of North Carolina at Chapel Hill

Grace K. Dy

Roswell Park Comprehensive Cancer Center

Scott Antonia

Moffitt Cancer Center

Leora Horn

Vanderbilt University Medical Center

Researcher Info

h-index: 1
Publications: 1
Citations: 1,406
Institution: Institut Gustave Roussy

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-1565-8310

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.